Home
Finance & valuation

Finance & valuation

How a patent dispute with 10x helped decimate NanoString’s stock price

Recent $31 million damages award has dealt a further blow to the company's faltering share value

Eligibility and PTAB reform bills spark debate at IAM event

IAM Connect: Patent Policy and Litigation delved deeply into Section 101 legislation, reform efforts at the Patent Trial and Appeal Board, and reactions to the European Commission's SEP proposal

Coming to America: funding for small innovators seeking patents to enter the US

We spotlight IP funding programmes in Singapore, Germany, China, and the European Union that incentivise small-to-medium-sized enterprises to globalise their patent portfolios

Latest content

Chinese lidar manufacturer paid $20 million upfront plus ongoing royalties to settle Velodyne dispute

Hesai Photonics Technology reveals monetary details of settlement, which also involves ongoing royalty payments through 2030

22 January 2021

Six life sciences IP dealmaking trends to watch out for in 2021

Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year

19 January 2021

Subsidies still matter in China’s patent world, but focus is shifting overseas

USPTO report on non-market patent incentives shows how Chinese applicants are being encouraged to obtain more foreign rights

14 January 2021

South Korea's Intellectual Discovery is in the process of becoming a big league, mainstream NPE

A year after a major capital infusion and a change of leadership, the firm has notched some notable settlements in the US and laid the groundwork for new assertion campaigns

08 January 2021

LG Electronics hooks up with IP Bridge as fund looks beyond Japan

Licensing business that shed state sponsorship last year partners with Korean patent powerhouse in latest acquisition

05 January 2021

The keys to effective IP monetisation

Patent licensing is as much an art as it is a science, explain some of those featured in the new IAM Strategy 300 Global Leaders guide

22 December 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies.

22 December 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver

16 December 2020

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models

12 December 2020

New patent politics put US public-private partnerships under threat, says BIO’s IP chief

In an exclusive interview, Hans Sauer talks of concerns over a shift in federal strategy and argues that government research funding should not be seen as a commercial investment

03 December 2020

Unlock unlimited access to all IAM content